Colorectal cancer stem cells: Biology and therapeutic implications

Current Colorectal Cancer Reports

Volumn 7, Issue 2, 2011, Pages 128-135

  Wilson, Brian J ^a   Schatton, Tobias ^b   Frank, Markus H ^a   Frank, Natasha Y ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

5 FU; ABCB5; ALDH1; APC; Aurora A kinase; BMP4; CD133; CD166; CD44; Chemoresistance; Colorectal cancer; ESA; Il 4; Lgr5; Notch; Oxaliplatin; Radioresistance; SMAD4; Stem cells; Targeting; Therapy; Wnt

Indexed keywords

ALDEHYDE DEHYDROGENASE; APC PROTEIN; AURORA A KINASE; AURORA KINASE INHIBITOR; AVE 1642; BETA CATENIN; BEVACIZUMAB; BONE MORPHOGENETIC PROTEIN 4; CAMPTOTHECIN; CD133 ANTIGEN; CELL SURFACE MARKER; CETUXIMAB; DNA; DOXORUBICIN; EPITHELIAL CELL ADHESION MOLECULE; FLUOROURACIL; GAMMA SECRETASE INHIBITOR; INTERLEUKIN 4; METHOTREXATE; NEUTRALIZING ANTIBODY; NOTCH RECEPTOR; OXALIPLATIN; RALTITREXED; SOMATOMEDIN; THYMOSIN BETA4; TUMOR MARKER; UNINDEXED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; WNT PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ANTIGEN EXPRESSION; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CELL; CANCER CONTROL; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER STEM CELL; CANCER SURVIVAL; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CARCINOGENICITY; CELL CYCLE G2 PHASE; CELL DEATH; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL RENEWAL; CHEMORADIOTHERAPY; COLON POLYPOSIS; COLORECTAL CANCER; COLORECTAL CANCER STEM CELL; CYTOLOGY; CYTOTOXICITY; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SCREENING; DRUG TARGETING; DRUG TUMOR LEVEL; EXTRACELLULAR MATRIX; GENE EXPRESSION; GENE MUTATION; GENE SILENCING; HEREDITY; HUMAN; MELANOMA; METASTASIS; MOLECULAR CLONING; MORPHOLOGY; MULTIDRUG RESISTANCE; NONHUMAN; ONCOGENE; PHENOTYPE; PROGENY; PROGNOSIS; RADIATION DOSE; REVIEW; TARGET CELL; TUMOR GROWTH; TUMOR SUPPRESSOR GENE; XENOTRANSPLANTATION;

EID: 80051800347     PISSN: 15563790     EISSN: 15563804     Source Type: Journal    
DOI: 10.1007/s11888-011-0093-2     Document Type: Review

References (77)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71-96. (Pubitemid 351521864)
2. Markowitz SD, Bertagnolli MM. Molecular origins of cancer: molecular basis of colorectal cancer. N Engl J Med. 2009;361:2449-60.
3. Frank NY, Schatton T, Frank MH: The therapeutic promise of the cancer stem cell concept. J Clin Invest. 2010;120:41-50.
4. Zhou BB, Zhang H, Damelin M, et al. Tumour-initiating cells: challenges and opportunities for anticancer drug discovery. Nat Rev Drug Discov. 2009;8:806-23.
5. Vogelstein B, Fearon ER, Hamilton SR, et al. Genetic alterations during colorectal-tumor development. N Engl J Med. 1988;319:525-32.
6. Kinzler KW, Nilbert MC, Vogelstein B, et al. Identification of a gene located at chromosome 5q21 that is mutated in colorectal cancers. Science. 1991;251:1366-70. (Pubitemid 21916922)
7. Nishisho I, Nakamura Y, Miyoshi Y, et al. Mutations of chromosome 5q21 genes in FAP and colorectal cancer patients. Science. 1991;253:665-9. (Pubitemid 21917200)
8. Morin PJ, Sparks AB, Korinek V, et al. Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science. 1997;275:1787-90. (Pubitemid 27136715)
9. Howe JR, Bair JL, Sayed MG, et al. Germline mutations of the gene encoding bone morphogenetic protein receptor 1A in juvenile polyposis. Nat Genet. 2001;28:184-7. (Pubitemid 32538067)
10. Howe JR, Roth S, Ringold JC, et al. Mutations in the SMAD4/DPC4 gene in juvenile polyposis. Science. 1998;280:1086-8. (Pubitemid 28234951)
11. Thiagalingam S, Lengauer C, Leach FS, et al. Evaluation of candidate tumour suppressor genes on chromosome 18 in colorectal cancers. Nat Genet. 1996;13:343-6. (Pubitemid 26230501)
12. Bellacosa A, Genuardi M, Anti M, et al. Hereditary nonpolyposis colorectal cancer: review of clinical, molecular genetics, and counseling aspects. Am J Med Genet. 1996;62:353-64.
13. Bruce WR, Van Der Gaag H. A quantitative assay for the number of murine lymphoma cells capable of proliferation in vivo. Nature. 1963;199:79-80.
14. Hamburger AW, Salmon SE. Primary bioassay of human tumor stem cells. Science. 1977;197:461-3.
15. Brunschwig A, Southam CM, Levin AG. Host resistance to cancer. Clinical experiments by homotransplants, autotransplants and admixture of autologous leucocytes. Ann Surg. 1965;162:416-25.
16. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature. 2001;414:105-11. (Pubitemid 33041634)
17. Al-Hajj M, Wicha MS, Benito-Hernandez A, et al. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A. 2003;100:3983-8. (Pubitemid 36418143)
18. Singh SK, Hawkins C, Clarke ID, et al. Identification of human brain tumour initiating cells. Nature. 2004;432:396-401. (Pubitemid 39551674)
19. O'Brien CA, Pollett A, Gallinger S, Dick JE: A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature. 2007;445:106-110. (Pubitemid 46067310)
20. Ricci-Vitiani L, Lombardi DG, Pilozzi E, et al.: Identification and expansion of human colon-cancer-initiating cells. Nature. 2007;445:111-115. (Pubitemid 46067311)
21. Dalerba P, Dylla SJ, Park IK, et al.: Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci U S A. 2007;104:10158-10163. (Pubitemid 47175279)
22. Schatton T, Murphy GF, Frank NY, et al. Identification of cells initiating human melanomas. Nature. 2008;451:345-9.
23. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med. 1997;3:730-7. (Pubitemid 27298715)
24. Lapidot T, Sirard C, Vormoor J, et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature. 1994;367:645-8. (Pubitemid 24067706)
25. Boiko AD, Razorenova OV, van de Rijn M, et al.: Human melanoma-initiating cells express neural crest nerve growth factor receptor CD271. Nature. 2010;466:133-7.
26. Huang EH, Hynes MJ, Zhang T, et al. Aldehyde dehydrogenase 1 is a marker for normal and malignant human colonic stem cells (SC) and tracks SC overpopulation during colon tumorigenesis. Cancer Res. 2009;69:3382-9.
27. Shmelkov SV, Butler JM, Hooper AT, et al. CD133 expression is not restricted to stem cells, and both CD133+ and CD133-metastatic colon cancer cells initiate tumors. J Clin Invest. 2008;118:2111-20. (Pubitemid 351872330)
28. Li G, Liu C, Yuan J, et al. CD133(+) single cell-derived progenies of colorectal cancer cell line SW480 with different invasive and metastatic potential. Clin Exp Metastasis. 2010;27:517-27.
29. Vermeulen L, Todaro M, de Sousa Mello F, et al. Single-cell cloning of colon cancer stem cells reveals a multi-lineage differentiation capacity. Proc Natl Acad Sci U S A. 2008;105:13427-32.
30. Weichert W, Knosel T, Bellach J, et al. ALCAM/CD166 is overexpressed in colorectal carcinoma and correlates with shortened patient survival. J Clin Pathol. 2004;57:1160-4. (Pubitemid 39486521)
31. Frank NY, Margaryan A, Huang Y, et al. ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma. Cancer Res. 2005;65:4320-33. (Pubitemid 40775671)
32. Haraguchi N, Ohkuma M, Sakashita H, et al. CD133+CD44+ population efficiently enriches colon cancer initiating cells. Ann Surg Oncol. 2008;15:2927-33.
33. Ginestier C, Korkaya H, Dontu G, et al. The cancer stem cell: the breast cancer driver. Med Sci (Paris). 2007;23:1133-9.
34. Barker N, van Es JH, Kuipers J, et al. Identification of stem cells in small intestine and colon by marker gene Lgr5. Nature. 2007;449:1003-7. (Pubitemid 350014593)
35. Barker N, Ridgway RA, van Es JH, et al. Crypt stem cells as the cells-of-origin of intestinal cancer. Nature. 2009;457:608-11.
36. Zhu L, Gibson P, Currle DS, et al. Prominin 1 marks intestinal stem cells that are susceptible to neoplastic transformation. Nature. 2009;457:603-7.
37. Du L, Wang H, He L, et al. CD44 is of functional importance for colorectal cancer stem cells. Clin Cancer Res. 2008;14:6751-60.
38. Zeilstra J, Joosten SP, Dokter M, et al. Deletion of the WNT target and cancer stem cell marker CD44 in Apc(Min/+) mice attenuates intestinal tumorigenesis. Cancer Res. 2008;68:3655-61.
39. Ponta H, Sherman L, Herrlich PA. CD44: from adhesion molecules to signalling regulators. Nat Rev Mol Cell Biol. 2003;4:33-45. (Pubitemid 36077255)
40. Ishimoto T, Oshima H, Oshima M, et al. CD44+ slow-cycling tumor cell expansion is triggered by cooperative actions of Wnt and prostaglandin E2 in gastric tumorigenesis. Cancer Sci. 2010;101:673-8.
41. Dissanayake SK, Wade M, Johnson CE, et al. The Wnt5A/protein kinase C pathway mediates motility in melanoma cells via the inhibition of metastasis suppressors and initiation of an epithelial to mesenchymal transition. J Biol Chem. 2007;282:17259-71. (Pubitemid 47093253)
42. Vermeulen L, De Sousa EMF, van der Heijden M, et al.: Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nat Cell Biol. 2010;12:468-476.
43. Ong CW, Kim LG, Kong HH, et al. CD133 expression predicts for non-response to chemotherapy in colorectal cancer. Mod Pathol. 2010;23:450-7.
44. Liu Z, Qiu M, Tang QL, et al. Establishment and biological characteristics of oxaliplatin-resistant human colon cancer cell lines. Chin J Cancer. 2010;29:661-7.
45. Dallas NA, Xia L, Fan F, et al.: Chemoresistant colorectal cancer cells, the cancer stem cell phenotype, and increased sensitivity to insulin-like growth factor-I receptor inhibition. Cancer Res. 2009;69:1951-1957.
46. Todaro M, Alea MP, Di Stefano AB, et al.: Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4. Cell Stem Cell. 2007;1:389-402. (Pubitemid 47506537)
47. Cammareri P, Scopelliti A, Todaro M, et al.: Aurora-a is essential for the tumorigenic capacity and chemoresistance of colorectal cancer stem cells. Cancer Res. 2010;70:4655-4665.
48. Song B, Wang Y, Xi Y, et al.: Mechanisms of chemoresistance mediated by mIR-140 in human osteosarcoma and colon cancer cells. Oncogene. 2010, 28:4065-4074.
49. Song B, Wang Y, Titmus MA, et al.: Molecular mechanism of chemoresistance by miR-215 in osteosarcoma and colon cancer cells. Mol Cancer. 2010;9:96.
50. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer. 2002;2:48-58. (Pubitemid 37328807)
51. Riordan JR, Deuchars K, Kartner N, et al. Amplification of Pglycoprotein genes in multidrug-resistant mammalian cell lines. Nature. 1985;316:817-9. (Pubitemid 15003740)
52. Frank NY, Pendse SS, Lapchak PH, et al. Regulation of progenitor cell fusion by ABCB5 P-glycoprotein, a novel human ATP-binding cassette transporter. J Biol Chem. 2003;278:47156-65. (Pubitemid 37452302)
53. Huang Y, Anderle P, Bussey KJ, et al. Membrane transporters and channels: role of the transportome in cancer chemosensitivity and chemoresistance. Cancer Res. 2004;64:4294-301. (Pubitemid 38802436)
54. Elliott AM, Al-Hajj MA. ABCB8 mediates doxorubicin resistance in melanoma cells by protecting the mitochondrial genome. Mol Cancer Res. 2009;7:79-87.
55. Cheung ST, Cheung PF, Cheng CK, et al.: Granulin-Epithelin Precursor and ATP-Dependent Binding Cassette (ABC)B5 Regulate Liver Cancer Cell Chemoresistance. Gastroenterology. 2010;140:344-55.
56. Fukunaga-Kalabis M, Martinez G, Nguyen TK, et al.: Tenascin-C promotes melanoma progression by maintaining the ABCB5-positive side population. Oncogene. 2010;29:6115-24.
57. Frank NY, Frank MH. ABCB5 gene amplification in human leukemia cells. Leuk Res. 2009;33:1303-5.
58. Bao S, Wu Q, McLendon RE, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 2006;444:756-60. (Pubitemid 44949604)
59. Saigusa S, Tanaka K, Toiyama Y, et al.: Clinical Significance of CD133 and Hypoxia Inducible Factor-1alpha Gene Expression in Rectal Cancer after Preoperative Chemoradiotherapy. Clin Oncol (R Coll Radiol) In-Press.
60. Saigusa S, Tanaka K, Toiyama Y, et al. Immunohistochemical features of CD133 expression: association with resistance to chemoradiotherapy in rectal cancer. Oncol Rep. 2010;24:345-50.
61. Meyerhardt JA, Mayer RJ. Systemic therapy for colorectal cancer. N Engl J Med. 2005;352:476-87.
62. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004;351:337-45. (Pubitemid 38944402)
63. Takahashi Y, Kitadai Y, Bucana CD, et al. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res. 1995;55:3964-8.
64. Fan F, Wey JS, McCarty MF, et al. Expression and function of vascular endothelial growth factor receptor-1 on human colorectal cancer cells. Oncogene. 2005;24:2647-53. (Pubitemid 40593092)
65. Fodde R, Smits R, Clevers H. APC, signal transduction and genetic instability in colorectal cancer. Nat Rev Cancer. 2001;1:55-67. (Pubitemid 33741881)
66. Lepourcelet M, Chen YN, France DS, et al.: Small-molecule antagonists of the oncogenic Tcf/beta-catenin protein complex. Cancer Cell. 2004;5:91-102. (Pubitemid 38121599)
67. Sikandar SS, Pate KT, Anderson S, et al.: NOTCH signaling is required for formation and self-renewal of tumor-initiating cells and for repression of secretory cell differentiation in colon cancer. Cancer Res. 2010;70:1469-78.
68. van Es JH, van Gijn ME, Riccio O, et al.: Notch/gamma-secretase inhibition turns proliferative cells in intestinal crypts and adenomas into goblet cells. Nature. 2005;435:959-963. (Pubitemid 40896322)
69. Haramis AP, Begthel H, van den Born M, et al. De novo crypt formation and juvenile polyposis on BMP inhibition in mouse intestine. Science. 2004;303:1684-6. (Pubitemid 38338329)
70. Kodach LL, Bleuming SA, Musler AR, et al. The bone morphogenetic protein pathway is active in human colon adenomas and inactivated in colorectal cancer. Cancer. 2008;112:300-6.
71. Lombardo Y, Scopelliti A, Cammareri P, et al.: Bone Morphogenetic Protein 4 Induces Differentiation of Colorectal Cancer StemCells and Increases Their Response to Chemotherapy in Mice. Gastroenterology. 2011;140:297-309.
72. Leavitt J, Gunning P, Kedes L, Jariwalla R. Smooth muscle alphaaction is a transformation-sensitive marker for mouse NIH 3 T3 and Rat-2 cells. Nature. 1985;316:840-2. (Pubitemid 15003747)
73. Ricci-Vitiani L, Mollinari C, di Martino S, et al.: Thymosin beta4 targeting impairs tumorigenic activity of colon cancer stem cells. FASEB J. 2010;24:4291-4301.
74. Bui T, Thompson CB. Cancer's sweet tooth. Cancer Cell. 2006;9:419-20. (Pubitemid 43832194)
75. Kim JW, Dang CV. Cancer's molecular sweet tooth and the Warburg effect. Cancer Res. 2006;66:8927-30. (Pubitemid 44521105)
76. Mantel C, Broxmeyer HE. Sirtuin 1, stem cells, aging, and stem cell aging. Curr Opin Hematol. 2008;15:326-31.
77. Akao Y, Noguchi S, Iio A, et al.: Dysregulation of microRNA-34a expression causes drug-resistance to 5-FU in human colon cancer DLD-1 cells. Cancer Lett. 2011;300:197-204.